Polymorphism of genes involved in purine metabolism (XDH, AOX1, MOCOS) in kidney transplant recipients receiving azathioprine

Therapeutic Drug Monitoring

Volumn 34, Issue 3, 2012, Pages 266-274

  Kurzawski, Mateusz ^a   Dziewanowski, Krzysztof ^b   Safranow, Krzysztof ^a   Drozdzik, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Regional Hospital   (Poland)

Author keywords

Aldehyde oxidase1 (AOX1); Azathioprine (AZA); Genetic polymorphism; Kidney transplantation; Molybdenum cofactor sulfurase (MOCOS); Xanthine dehydrogenase (XDH)

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALDEHYDE OXIDASE; ALDEHYDE OXIDASE 1; AZATHIOPRINE; BASILIXIMAB; CEFUROXIME; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; ENZYME; MOLYBDENUM COFACTOR SULFURASE; PREDNISONE; PURINE; UNCLASSIFIED DRUG; XANTHINE DEHYDROGENASE;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ALLELE; AOX1 GENE; ARTICLE; BONE MARROW TOXICITY; CHILD; CLINICAL PRACTICE; COHORT ANALYSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; FEMALE; GENE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MOCOS GENE; NEPHROTOXICITY; NEUROTOXICITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PURINE METABOLISM; RECIPIENT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TPMT GENE; WILD TYPE; XDH GENE;

ADOLESCENT; ADULT; AGED; ALDEHYDE OXIDASE; ANTIMETABOLITES; AZATHIOPRINE; CHILD; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SULFURTRANSFERASES; XANTHINE DEHYDROGENASE; YOUNG ADULT;

EID: 84861232022     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31824aa681     Document Type: Article

References (26)

1. Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology. 2000;61:136-146.
2. Zhou S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol. 2006;1:119-128.
3. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662. (Pubitemid 10061685)
4. Lennard L, Gibson BES, Nicole T, et al. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child. 1993;69:577-579. (Pubitemid 23355853)
5. Kurzawski M, Dziewanowski K, Lener A, et al. TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol. 2009;65:533-540.
6. Von Ahsen N, Oellerich M, Armstrong VW. Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotypephenotype correlation and promoter function. Ther Drug Monit. 2008; 30:16-22. (Pubitemid 351161094)
7. Van Dieren JM, Hansen BE, Kuipers EJ, et al. Meta-analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2007;26:643-652. (Pubitemid 47246201)
8. Smith MA, Marinaki AM, Arenas M, et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther. 2009;30:375-384.
9. Xu P, Huecksteadt TP, Hoidal JR. Molecular cloning and characterization of the human xanthine dehydrogenase gene (XDH). Genomics. 1996; 34:173-180. (Pubitemid 26172841)
10. Zimm S, Collins JM, O'Neill D, et al. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther. 1983;34:810-817. (Pubitemid 14219930)
11. Keuzenkamp-Jansen CW, van Baal JM, De Abreu RA, et al. Detection and identification of 6-methylmercapto-8-hydoxypurine, a major metabolite of 6-mercaptopurine, in plasma during intravenous administration. Clin Chem. 1996;42:380-386. (Pubitemid 26080922)
12. Ichida K, Matsumura T, Sakuma R, et al. Mutation of human molybdenum cofactor sulfurase gene is responsible for classical xanthinuria type II. Biochem Biophys Res Commun. 2001;282:1194-1200. (Pubitemid 32912852)
13. Thervet E, Anglicheau D, Legendre C, et al. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit. 2008;30:143-150. (Pubitemid 351521640)
14. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008;64: 753-767.
15. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 2004;14:181-187. (Pubitemid 38373112)
16. Stocco G, Martelossi S, Sartor F, et al. Prevalence of methylenetetrahydrofolate reductase polymorphisms in young patients with inflammatory bowel disease. Dig Dis Sci. 2006;51:474-479.
17. Ban H, Andoh A, Imaeda H, et al. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2010;45:1014-1021.
18. Bourgine J, Garat A, Allorge D, et al. Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response? Pharmacogenet Genomics. 2011;21:313-324.
19. Shipkova M, Franz J, Abe M, et al. Association between adverse effects under azathioprine therapy and inosine triphosphate pyrophosphatase activity in patients with chronic inflammatory bowel disease. Ther Drug Monit. 2011;33:321-328.
20. Rashidi MR, Beedham C, Smith JS, et al. In vitro study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase. Drug Metab Pharmacokinet. 2007;22:299-306.
21. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther. 1991;50:663-672.
22. Kudo M, Sasaki T, Ishikawa M, et al. Kinetics of 6-thioxanthine metabolism by allelic variants of xanthine oxidase. Drug Metab Pharmacokinet. 2010;25:361-366.
23. Kudo M, Sasaki T, Ishikawa M, et al. Functional characterization of genetic polymorphisms identified in the promoter region of the xanthine oxidase gene. Drug Metab Pharmacokinet. 2010;25:599-604.
24. Ikegami T, Nishino T. The presence of desulfo xanthine dehydrogenase in purified and crude enzyme preparations from rat liver. Arch Biochem Biophys. 1986;247:254-260. (Pubitemid 16077528)
25. Yamamoto T, Moriwaki Y, Takahashi S, et al. Identification of a new point mutation in the human molybdenum cofactor sulferase gene that is responsible for xanthinuria type II. Metabolism. 2003;52:1501-1504. (Pubitemid 37461122)
26. Jelliffe R, Schumitzky A, Bayard D, et al. Human Genetic variation, Population Pharmacokinetic-dynamic models, Bayesian feedback control, and maximally precise Individualized drug dosage regimens. Curr Pharmacogenomics Person Med. 2009;7:249-262.